Naproxen-PC: A GI safe and highly effective anti-inflammatory

Inflammopharmacology

Volumn 17, Issue 1, 2009, Pages 1-5

  Lichtenberger, L M ^a   Romero, J J ^b   Dial, E J ^a   Moore, J E ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b PLx Pharma Inc   (United States)

Author keywords

Cyclooxygenase; Inflammation; Naproxen; Phosphatidylcholine; Prostaglandin; Ulcer

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; N(G) NITROARGININE METHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLCHOLINE; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; INFLAMMATION; INTESTINAL BLEEDING; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SYNOVIAL FLUID;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EDEMA; GASTROINTESTINAL HEMORRHAGE; INFLAMMATION; LECITHINS; NAPROXEN; RATS; SOYBEANS; SYNOVIAL FLUID;

EID: 59049097723     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-008-8047-2     Document Type: Article

References (28)

1. Anand, B.S., Romero, J.J., Sanduja, S.K. & Lichtenberger, L.M. (1999) Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol, 94, 1818-22.
2. Biskupiak, J.E., Brixner, D.I., Howard, K. & Oderda, G.M. (2006) Gastrointestinal complications of over-the-counter nonsteroidal anti-inflammatory drugs. J Pain Palliat Care Pharmacother, 20, 7-14.
3. Bresalier, R.S., Sandler, R.S. Quan, H., Bolognese, J.A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M.A., & Baron, J.A. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 352, 1092-102.
4. Budenholzer, B.R. (2002) Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. BMJ, 325, 161; author reply 161.
5. Butler, B.D., Lichtenberger, L.M., & Hills, B. A. (1983) Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol, 244, G645-51.
6. Chan, F. K. (2006) Primer: managing NSAID-induced ulcer complications - balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol, 3, 563-73.
7. Cronstein, B. N. (2002) Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med, 69 Suppl 1, SI13-9.
8. Darling, R. L., Romero, J. J., Dial, E. J., Akunda, J. K., Langenbach, R. & Lichtenberger, L.M. (2004) The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology, 127, 94-104.
9. Deeks, J. J., Smith, L. A. & Bradley, M. D. (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ, 325, 619.
10. Farkouh, M. E., Greenberg, J. D., Jeger, R. V., Ramanathan, K., Verheugt, F. W., Chesebro, J. H., Kirshner, H., Hochman, J. S., Lay, C. L., Ruland, S., Mellein, B., Matchaba, P. T., Fuster, V. & Abramson, S. B. (2007) Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis, 66, 764-70.
11. Garcia Rodriguez, L. A. & Jick, H. (1994) Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343, 769-72.
12. Gionannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C. & Speizer, F. E. (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med, 333, 609-14.
13. Giraud, M. N., Motta, C., Romero, J. J., Bommalaer, G. & Lichtenberger, L.M. (1999) Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol, 57, 247-54.
14. Goddard, P. J., Hills, B. A. & Lichtenberger, L.M. (1987) Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity? Am J Physiol, 252, G421-30.
15. Goddard, P. J., Kao, Y. C. & Lichtenberger, L.M. (1990) Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel. Gastroenterology, 98, 361-70.
16. Hills, B. A., Butler, B. D. & Lichtenberger, L.M. (1983) Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach. Am J Physiol, 244, G561-8.
17. Insel, P. A. (1996) Analgesic-Antipyretic and antiinflammatory agents and drugs emplyed in the treatment of gout. In Hardman, J. G. (Ed.) Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, McGraw-Hill.
18. Jüni, P., Rutjes, A. W. & Dieppe, P. A. (2002) Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ, 324, 1287-8.
19. Lanza, F. L., Marathi, U., Anand, B. S. & Lichtenberger, L.M. (2008) Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther, 28, 431-442.
20. Lichtenberger, L.M. (1995) The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol, 57, 565-83.
21. Lichtenberger, L.M., Graziani, L. A., Dial, E. J., Butler, B. D. & Hills, B. A. (1983) Role of surface-active phospholipids in gastric cytoprotection. Science, 219, 1327-9.
22. Lichtenberger, L.M., Romero, J. J., De Ruijter, W. M., Behbod, F., Darling, R., Ashraf, A. Q. & Sanduja, S. K. (2001) Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J Pharmacol Exp Ther, 298, 279-87.
23. Lichtenberger, L.M., Romero, J. J. & Dial, E. J. (2007) Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol, 150, 913-9.
24. Lichtenberger, L.M., Wang, Z. M., Romero, J. J., Ulloa, C., Perez, J. C., Giraud, M. N. & Barreto, J. C. (1995) Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med, 1, 154-8.
25. Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W. & Verburg, K. M. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med, 352, 1081-91.
26. Solomon, S. D., McMurray, J. J., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Sauber, A., Hawk, E. & Bertagnolli, M. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 352, 1071-80.
27. Watson, D. J., Rhodes, T., Cai, B. & Guess, H. A. (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med, 162, 1105-10.
28. Zarraga, I. G. & Schwarz, E. R. (2007) Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol, 49, 1-14.